Literature DB >> 30782385

Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.

Yoshihito Kogure1, Yukira Ishii2, Masahide Oki2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30782385     DOI： 10.1016/j.jtho.2018.11.025

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.

Authors:  Aaron T Ciner; Howard S Hochster; David A August; Darren R Carpizo; Kristen R Spencer
Journal:  Immunotherapy       Date:  2021-07-21       Impact factor: 4.040

2.  Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.

Authors:  Alessandro Ceschi; Roberta Noseda; Karine Palin; Katia Verhamme
Journal:  Front Pharmacol       Date:  2020-05-04       Impact factor: 5.810

3.  Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.

Authors:  Makiko Yomota; Kie Mirokuji; Masahiro Sakaguchi; Yasuyuki Kitahara; Fangyi Chin; Keigo Setoguchi; Yukio Hosomi
Journal:  Intern Med       Date:  2021-03-29       Impact factor: 1.271

4.  Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.

Authors:  Peng-Bo Deng; Juan Jiang; Cheng-Ping Hu; Li-Ming Cao; Min Li
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

5.  Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.

Authors:  Meng Zhang; Yuan Cheng; Yan Hu; Ligong Nie
Journal:  Thorac Cancer       Date:  2022-04-05       Impact factor: 3.223

6.  Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.

Authors:  Thomas M Braun; Francois Mercier
Journal:  Stat Med       Date:  2022-06-05       Impact factor: 2.497

7.  Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.

Authors:  Paul Sackstein; Jacob Zaemes; Chul Kim
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.